BHVN
HEALTHCAREBiohaven Ltd
$10.04+0.33 (+3.40%)PRE
Live · NYSE · May 9, Close
AI Insight
What's Moving BHVN Today?
No stock-specific AI insight has been generated for BHVN yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$7.48$22.05
$10.04
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-5.57
Dividend Yield—
Dividend / Share—
ROE-3.3%
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding150.6M
BHVN News
20 articles- Biohaven (BHVN) Is Up 9.1% After Narrower Q1 Loss And New Mixed Shelf Registration - What's ChangedYahoo Finance·May 6, 2026
- Biohaven Ltd. (BHVN) Upgraded to Buy: Here's WhyYahoo Finance·May 5, 2026
- A Look At Biohaven (BHVN) Valuation After Narrower Q1 Loss And New Pivotal Trial And Funding PlansYahoo Finance·May 5, 2026
- Biohaven Reports Recent Business Developments and First Quarter 2026 Financial ResultsYahoo Finance·May 4, 2026
- KCNQ2 Developmental and Epileptic Encephalopathy Market Research Report 2025-2035, Competitive Analysis of Biohaven, Xenon Pharma, Lundbeck, Praxis Precision Medicines, NeuShen TherapeuticsYahoo Finance·Apr 28, 2026
- Moderate Buy Rating Seen For Biohaven Ltd. (BHVN)Yahoo Finance·Apr 22, 2026
- Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy RatingYahoo Finance·Apr 20, 2026
- Why Biohaven Stock Crushed it on MondayMotley Fool·Apr 13, 2026
- Here is why Biohaven (BHVN) is Among the Top Healthcare Stocks Insiders Are BuyingYahoo Finance·Apr 12, 2026
- Biohaven (BHVN) Fuels Confidence With Encouraging Azetukalner DataYahoo Finance·Apr 1, 2026
- Can Biohaven (BHVN) Redefine Obesity Treatment By Targeting Lean Mass Preservation With Taldefgrobep?Yahoo Finance·Mar 30, 2026
- Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep AlfaYahoo Finance·Mar 27, 2026
- Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround PotentialMotley Fool·Mar 23, 2026
- This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in CashMotley Fool·Mar 22, 2026
- Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes EnrollmentYahoo Finance·Mar 19, 2026
- uniQure stock surges 36% on FDA official’s departureYahoo Finance·Mar 9, 2026
- Biohaven Reshapes Pipeline And Funding As Late Stage Trials ApproachYahoo Finance·Mar 4, 2026
- SSR Mining Stock Up 180% as New $5 Million Stake Signals Gold ConvictionMotley Fool·Mar 3, 2026
- Nuvation Bio Stock Up 130% This Past Year as One Fund Discloses $3 Million BuyMotley Fool·Mar 3, 2026
- Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 2, 2026
All 20 articles loaded
Price Data
Open$9.79
Previous Close$9.71
Day High$10.29
Day Low$9.71
52 Week High$22.05
52 Week Low$7.48
52-Week Range
$7.48$22.05
$10.04
Fundamentals
Market Cap$1.5B
P/E Ratio—
EPS$-5.57
Dividend Yield—
Dividend / Share—
ROE-3.3%
Profit Margin—
Debt / Equity—
Trading
Volume2.0M
Avg Volume (10D)—
Shares Outstanding150.6M
About Biohaven Ltd
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders in the United States. The company is headquartered in New Haven, Connecticut.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNYSE
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—